Share Prices & Company Research

Market News

01 Mar 2021 | 15:36

Sensyne Health gets UK approval for 'SYNE-COV' algorithm

(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Monday that its 'SYNE-COV' machine learning algorithm for Covid-19 risk prediction has achieved regulatory approval for use in the UK. The AIM-traded firm said SYNE-COV analyses more than 60 variables in the patient electronic health record to generate a prediction of the likelihood of a Covid-positive patient developing severe disease, requiring ventilation or admission to intensive care.

It said it provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with Covid infection.

The SYNE-COV product was developed in collaboration with the Chelsea and Westminster Hospitals NHS Foundation Trust, and was the first algorithm developed from the 'SENSE' clinical and operational algorithm engine to achieve UK regulatory approval.

SENSE generates clinical AI algorithms, called 'SYNEs', from the analysis of data in patient electronic health records to provide decision support to clinicians.

The company said it had several algorithms currently in development across a number of medical conditions, which, subject to regulatory approval, it intended to market to healthcare providers in the UK and internationally.

Following regulatory approval, Sensyne said it was now able to market SYNE-COV across the UK.

It was planning to market the algorithm to NHS trusts in order to help them with Covid-19 preparedness, and to deploy the algorithm in good time for the 2021-2022 winter season.

"This is the first Sensyne clinical AI algorithm to achieve regulatory approval that has been developed using our SENSE clinical AI platform," said chief executive officer Lord Drayson.

"The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision making support.

"Achieving the first regulatory approval is an important milestone for the company, and we look forward to being able to roll SYNE-COV out to the NHS."

At 1105 GMT, shares in Sensyne Health were up 0.15% at 162.75p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 14th May 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.